AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drugnews2026-02-26T16:06:55+00:00February 26th, 2026|Endpoints News|
Accent axes a cancer study; Werewolf considers its optionsnews2026-02-25T15:38:29+00:00February 25th, 2026|Endpoints News|
Beam Therapeutics’ new PKU program; Protara’s bladder cancer datanews2026-02-24T15:35:10+00:00February 24th, 2026|Endpoints News|
Merck reorganizes; Blackstone to fund trials for J&J drugnews2026-02-23T14:25:25+00:00February 23rd, 2026|Endpoints News|
Candel prices offering, signs royalty deal; Calquence label expandsnews2026-02-20T14:57:17+00:00February 20th, 2026|Endpoints News|
Biogen stops part of an MS trial; Merck reports more Enflonsia datanews2026-02-19T15:55:48+00:00February 19th, 2026|Endpoints News|
Lilly’s Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido resultsnews2026-02-18T15:16:02+00:00February 18th, 2026|Endpoints News|
Six biotechs file for HKEX listing; Faraday Pharmaceuticals shuttersnews2026-02-17T15:52:53+00:00February 17th, 2026|Endpoints News|
Immunic’s private placement; Vertex’s cystic fibrosis data in young kidsnews2026-02-13T14:45:37+00:00February 13th, 2026|Endpoints News|
A pancreatic cancer approval; Seres cuts staffnews2026-02-12T15:10:19+00:00February 12th, 2026|Endpoints News|
